Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443), a biopharmaceutical company based in China, has entered into a partnership with fellow Chinese firm Chongqing Pharmaceutical (Group) Co., Ltd (CQP). Under this collaboration, Genrix Bio will utilize CQP’s extensive network and digital services to bolster the market launch of its innovative products, with a focus on addressing the needs of medical institutions and patients. Financial details of the agreement were not disclosed.
The strategic partnership aims to create a patient-centric model, harnessing complementary strengths and resource sharing to enhance market share and patient reach for the products involved. The two companies also plan to delve into deep collaborations across business models, technological innovation, and market strategy, aiming to strengthen their core competencies and establish a mutually beneficial business cooperation model. Genrix currently has four innovative products in late-stage development, with its lead product, the IL-17 inhibitor xeligekimab, currently under regulatory review for two indications: moderate to severe plaque psoriasis and axial spondyloarthritis. This partnership follows Genrix’s first step towards transitioning to a commercial-stage company with a distribution and retail-focused agreement with China Resource Medicine Commercial Holdings Ltd, announced in April this year.- Flcube.com
